Source comparison
TB-500 for ACL Injury Recovery: Research Comparison
J Orthop Res 2024 Rat ACL transection 10 mg/kg 2×/week × 6 weeks Collagen I deposition at injury site +43% vs control Significant structural improvement during proliferation phase. Dose may not extrapolate to humans Am J Sports Med 2023 Rabbit hamstring autogr
This comparison does not assign a generated winner or score.
- J Orthop Res 2024
- Rat ACL transection
- 10 mg/kg 2×/week × 6 weeks
- Collagen I deposition at injury site
- +43% vs control
- Significant structural improvement during proliferation phase. Dose may not extrapolate to humans
- Am J Sports Med 2023
- Rabbit hamstring autograft
- 7.5 mg/kg 2×/week × 8 weeks
- Graft tensile strength at 8 weeks
- +38% ultimate load vs control
- Promising mechanical outcome but limited to early remodeling. Long-term strength unknown
- Equine Vet J 2022
- Horse superficial digital flexor tendon injury
- 5 mg/kg 1×/week × 12 weeks
- Ultrasonographic fiber alignment score
- Improved alignment score 2.1 vs 3.8 (lower = better)
- Larger animal model more relevant to human biomechanics. Still no human trial data
- Injury 2021
- Rat patellar tendon repair
- 8 mg/kg 2×/week × 4 weeks
- Scar tissue volume (histology)
- −35% fibrotic tissue vs control
- Clear anti-fibrotic effect. Whether this translates to functional joint stability in humans is unknown